Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Depreciation & Amortization (CF) (2017 - 2025)

Sutro Biopharma's Depreciation & Amortization (CF) history spans 9 years, with the latest figure at $1.9 million for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 5.61% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $7.6 million, up 7.12%, while the annual FY2024 figure was $7.2 million, 6.15% up from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $1.9 million at Sutro Biopharma, roughly flat from $1.9 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.9 million in Q1 2025 and bottomed at $1.1 million in Q3 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $1.7 million (2023), against an average of $1.6 million.
  • The largest YoY upside for Depreciation & Amortization (CF) was 28.62% in 2022 against a maximum downside of 2.79% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.3 million in 2021, then rose by 16.2% to $1.5 million in 2022, then increased by 12.24% to $1.7 million in 2023, then increased by 8.92% to $1.9 million in 2024, then rose by 1.71% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Depreciation & Amortization (CF) are $1.9 million (Q3 2025), $1.9 million (Q2 2025), and $1.9 million (Q1 2025).